Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. grew its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 45.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 227,479 shares of the company’s stock after buying an additional 71,214 shares during the quarter. Mirum Pharmaceuticals accounts for about 1.4% of Nan Fung Trinity HK Ltd.’s portfolio, making the stock its 25th largest holding. Nan Fung Trinity HK Ltd.’s holdings in Mirum Pharmaceuticals were worth $17,969,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. CWM LLC raised its holdings in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares during the period. MCF Advisors LLC raised its holdings in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares during the period. Jones Financial Companies Lllp raised its holdings in Mirum Pharmaceuticals by 34.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares during the period. Arizona State Retirement System raised its holdings in Mirum Pharmaceuticals by 2.6% in the 3rd quarter. Arizona State Retirement System now owns 10,984 shares of the company’s stock worth $805,000 after purchasing an additional 275 shares during the period. Finally, Comerica Bank raised its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $107.16 on Friday. The business has a 50 day simple moving average of $93.79 and a two-hundred day simple moving average of $86.06. Mirum Pharmaceuticals, Inc. has a 12 month low of $42.89 and a 12 month high of $112.00. The stock has a market capitalization of $6.53 billion, a P/E ratio of -7.87 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 10.84%. The firm had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. During the same period in the previous year, the company earned ($0.30) EPS. Mirum Pharmaceuticals’s revenue was up 43.3% compared to the same quarter last year. As a group, analysts predict that Mirum Pharmaceuticals, Inc. will post -8.25 EPS for the current fiscal year.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum jumped after investors reacted to positive Volixibat Phase 2b data in primary sclerosing cholangitis (PSC), which supports the company’s pipeline and has likely improved confidence in future growth. Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 Loss – Has The Bull Case Changed?
• Positive Sentiment: HC Wainwright raised its FY2027 earnings estimate for Mirum Pharmaceuticals to $0.70 per share from $0.63, suggesting stronger longer-term profitability expectations.
• Positive Sentiment: The firm also lifted its Q4 2026 EPS estimate to a smaller loss of $(0.06) from $(0.09), which points to improving near-term earnings momentum.
• Neutral Sentiment: HC Wainwright now expects Mirum to turn profitable in later periods, including $0.02 EPS in Q2 2027, $0.26 in Q3 2027, and $0.49 in Q4 2027, reinforcing a more constructive long-term view.
• Negative Sentiment: Despite the improved outlook, the analyst still sees losses through most of 2026, including a larger Q2 2026 loss estimate of $(0.58) and a Q3 2026 loss estimate of $(1.06), highlighting that profitability remains some time away.

Analyst Ratings Changes

A number of equities analysts recently weighed in on MIRM shares. HC Wainwright set a $185.00 price target on Mirum Pharmaceuticals in a report on Thursday. Morgan Stanley upped their price target on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday. Citizens Jmp reaffirmed a “market outperform” rating and issued a $132.00 price target on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Finally, TD Cowen upped their price target on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $136.42.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,985 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at $17,872,541.82. This represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joanne Quan sold 7,287 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the transaction, the insider directly owned 18,864 shares of the company’s stock, valued at $1,735,110.72. The trade was a 27.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 76,806 shares of company stock valued at $7,064,616. 14.36% of the stock is owned by insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.